Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,696,354 shares of the biotechnology company’s stock after purchasing an additional 44,306 shares during the period. Geode Capital Management LLC owned 1.78% of Sarepta Therapeutics worth $211,910,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter worth $31,000. Huntington National Bank increased its position in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Nkcfo LLC acquired a new position in Sarepta Therapeutics in the 2nd quarter valued at about $43,000. Riggs Asset Managment Co. Inc. lifted its holdings in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 197 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 0.6 %

Shares of NASDAQ:SRPT opened at $123.71 on Monday. The firm has a market cap of $11.82 billion, a PE ratio of 98.97 and a beta of 0.77. The company has a fifty day simple moving average of $123.12 and a 200 day simple moving average of $131.53. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $89.92 and a 12-month high of $173.25.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

SRPT has been the subject of a number of analyst reports. HC Wainwright cut their price objective on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a “sell” rating for the company in a research report on Tuesday, December 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Piper Sandler lowered their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. UBS Group increased their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.